Novel vaccines : VVaccinations in the near and distant future;Neuartige Impfstoffe : Impfen in naher und ferner Zukunft

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz

Volumn 52, Issue 11, 2009, Pages 1083-1090

  Wack, A ^a   Seubert, A ^b   Hilleringmann, M ^b  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Adjuvants; Genome; Proteome; Screening; Vaccine

Indexed keywords

VACCINE;

ARTICLE; DRUG DESIGN; FORECASTING; HUMAN; METHODOLOGY; VACCINATION; VIRUS INFECTION;

DRUG DESIGN; FORECASTING; HUMANS; VACCINATION; VACCINES; VIRUS DISEASES;

EID: 71349087004     PISSN: 14369990     EISSN: 14371588     Source Type: Journal    
DOI: 10.1007/s00103-009-0953-y     Document Type: Article

References (50)

1. Rappuoli R (2007) Bridging the knowledge gaps in vaccine design. Nat Biotechnol 25:1361-1366
2. Schneeweiß B, Pfleiderer M, Keller-Stanislawski B (2008) Impfsicherheit heute. Dtsch Ärztebl 105:34-35
3. Hacker J (2009) Impfziele und Impfprogramme in Deutschland - eine Bestandsaufnahme. In: Nationale Impfkonferenz, Mainz
4. Wack A, Rappuoli R (2005) Vaccinology at the beginning of the 21st century. Curr Opin Immunol 17:411-418
5. Hainz U, Jenewein B, Asch E et al (2005) Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine 23:3232-3235
6. Telford JL (2008) Bacterial genome variability and its impact on vaccine design. Cell Host Microbe 3:408-416
7. Pizza M, Scarlato V, Masignani V et al (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287:1816-1820
8. Giuliani MM, Adu-Bobie J, Comanducci M et al (2006) A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 103:10834-10839
9. Maione D, Margarit I, Rinaudo CD et al (2005) Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 309:148-150
10. Grifantini R, Bartolini E, Muzzi A et al (2002) Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol 20:914-921
11. Grifantini R, Sebastian S, Frigimelica E et al (2003) Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B. Proc Natl Acad Sci USA 100:9542-9547
12. Rodriguez-Ortega MJ, Norais N, Bensi G et al (2006) Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 24:191-197
13. Rodriguez-Ortega MJ, Luque I, Tarradas C, Barcena JA (2008) Overcoming function annotation errors in the Gram-positive pathogen Streptococcus suis by a proteomics-driven approach. BMC Genomics 9:588
14. Severin A, Nickbarg E, Wooters J et al (2007) Proteomic analysis and identification of Streptococcus pyogenes surface-associated proteins. J Bacteriol 189:1514-1522
15. Berlanda Scorza F, Doro F, Rodriguez-Ortega MJ et al (2008) Proteomics characterization of outer membrane vesicles from the extraintestinal pathogenic Escherichia coli DeltatolR IHE3034 mutant. Mol Cell Proteomics 7:473-485
16. Jacobsson S, Hedberg ST, Molling P et al (2009) Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 27:1579-1584
17. Tettelin H, Masignani V, Cieslewicz MJ et al (2005) Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial .,pan-genome". Proc Natl Acad Sci U S A 102:13950-13955
18. Tettelin H, Riley D, Cattuto C, Medini D (2008) Comparative genomics: the bacterial pan-genome. Curr Opin Microbiol 11:472-477
19. Medini D, Donati C, Tettelin H et al (2005) The microbial pan-genome. Curr Opin Genet Dev 15:589-594
20. Medini D, Serruto D, Parkhill J et al (2008) Microbiology in the post-genomic era. Nat Rev Microbiol 6:419-430
21. Mora M, Donati C, Medini D et al (2006) Microbial genomes and vaccine design: refinements to the classical reverse vaccinology approach. Curr Opin Microbiol 9:532-536
22. Pizza M, Covacci A, Bartoloni A et al (1989) Mutants of pertussis toxin suitable for vaccine development. Science 246:497-500
23. Song L, Hobaugh MR, Shustak C et al (1996) Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore. Science 274:1859-1866
24. Menzies BE, Kernodle DS (1994) Site-directed mutagenesis of the alpha-toxin gene of Staphylococcus aureus: role of histidines in toxin activity in vitro and in a murine model. Infect Immun 62:1843-1847
25. Menzies BE, Kernodle DS (1996) Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model. Infect Immun 64:1839-1841
26. Bubeck Wardenburg J, Schneewind O (2008) Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205:287-294
27. Dormitzer PR, Ulmer JB, Rappuoli R (2008) Structure- based antigen design: a strategy for next generation vaccines. Trends Biotechnol 26:659-667
28. Barouch DH (2008) Challenges in the development of an HIV-1 vaccine. Nature 455:613-619
29. Roux KH, Taylor KA (2007) AIDS virus envelope spike structure. Curr Opin Struct Biol 17:244-252
30. Srivastava IK, Stamatatos L, Legg H et al (2002) Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol 76:2835-2847
31. Srivastava IK, Stamatatos L, Kan E et al (2003) Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 77:11244-11259
32. Skehel JJ, Stevens DJ, Daniels RS et al (1984) A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci USA 81:1779-1783
33. Sui J, Hwang WC, Perez S et al (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16:265-273
34. Ekiert DC, Bhabha G, Elsliger MA et al (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324:246-251
35. Delgado MF, Coviello S, Monsalvo AC et al (2009) Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15:34-41
36. O'Hagan DT, Wack A, Podda A (2007) MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin Pharmacol Ther 82:740-744
37. Banzhoff A, Gasparini R, Laghi-Pasini F et al (2009) MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4:e4384
38. Guy B (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5:505-517
39. Wack A, Baudner BC, Hilbert AK et al (2008) Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26:552-561
40. Kool M, Soullie T, van Nimwegen M et al (2008) Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205:869-882
41. Lambrecht BN, Kool M, Willart MA, Hammad H (2009) Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 21:23-29
42. McLachlan JB, Shelburne CP, Hart JP et al (2008) Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med 14:536-541
43. Seubert A, Monaci E, Pizza M et al (2008) The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 180:5402-5412
44. Oosterhuis-Kafeja F, Beutels P, Van Damme P (2007) Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 25:2194-2212
45. Center KJ, Strauss A (2009) Safety experience with heptavalent pneumococcal CRM(197)-conjugate vaccine (Prevenar((R)) since vaccine introduction. Vaccine 27:3281-3284
46. Messina AF, Katz-Gaynor K, Barton T et al (2007) Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J 26:461-467
47. Verez-Bencomo V, Fernandez-Santana V, Hardy E et al (2004) A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 305:522-525
48. Ulmer JB, Valley U, Rappuoli R (2006) Vaccine manufacturing: challenges and solutions. Nat Biotechnol 24:1377-1383
49. Nichol KL, Treanor JJ (2006) Vaccines for seasonal and pandemic influenza. J Infect Dis 194 (Suppl 2):S111-S118
50. Mitragotri S (2005) Immunization without needles. Nat Rev Immunol 5:905-916